GROWTH HORMONE RELEASING HORMONE ANTAGONIST INFUSION IN ACROMEGALICS

肢端肥大症的特征是垂体腺生长激素瘤的生长激素(GH)高分泌。垂体肿瘤发生的机制(S)尚不清楚。为了研究下丘脑生长激素释放激素(GHRH)在肢端肥大症发病机制中的重要作用，我们建议研究10名肢端肥大症患者，他们将接受手术切除他们的脑垂体肿瘤。受试者将被允许进入GCRC为期10天。连续输注GHRH拮抗剂7天。在GHRH推注剂量前后将进行多次测试，以及对促甲状腺激素释放激素(TRH)推注剂量的反应。此外，在手术中切除的部分脑垂体瘤将由研究人员保留下来进行进一步的体外测试。这项研究将涉及(或排除)下丘脑GHRH作为生长激素腺瘤转化和功能亢进的促进剂。

Acromegaly is characterized by growth hormone(GH) hypersecretion from a pituitary somatotroph tumor. The mechanism(s) of pituitary tumorigenesis are unknown. To look at the possibility that hypothalamic growth hormone releasing hormone(GHRH) is important in the pathogenesis of acromegaly, we propose to study 10 acromegalic subjects who will be having surgery for removal of their pituitary tumor. Subjects will be admitted to the GCRC for 10 days. They will be given a continuous infusion of GHRH antagonist for 7 days. Numerous tests will be done before and after the GHRH bolus dose, and response to thyrotropin releasing hormone (TRH) bolus dose. In addition, part of the pituitary tumor removed during the operation will be retained by investigators for further in-vitro tests. This study will implicate (or exclude) hypothalamic GHRH as a promoter of somatrotroph adenomatous transformation and hyperfunction.